RU2642302C1 - Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов - Google Patents

Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов Download PDF

Info

Publication number
RU2642302C1
RU2642302C1 RU2016123808A RU2016123808A RU2642302C1 RU 2642302 C1 RU2642302 C1 RU 2642302C1 RU 2016123808 A RU2016123808 A RU 2016123808A RU 2016123808 A RU2016123808 A RU 2016123808A RU 2642302 C1 RU2642302 C1 RU 2642302C1
Authority
RU
Russia
Prior art keywords
actriib
gdf trap
polypeptide
sequence
seq
Prior art date
Application number
RU2016123808A
Other languages
English (en)
Russian (ru)
Inventor
Джасбир Сихра
Роберт Скотт ПИРСАЛЛ
Равиндра Кумар
Original Assignee
Акселерон Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/004659 external-priority patent/WO2010019261A1/en
Application filed by Акселерон Фарма Инк. filed Critical Акселерон Фарма Инк.
Application granted granted Critical
Publication of RU2642302C1 publication Critical patent/RU2642302C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2016123808A 2009-08-13 2010-08-13 Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов RU2642302C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels
US12/583,177 US8058229B2 (en) 2008-08-14 2009-08-13 Method of increasing red blood cell levels or treating anemia in a patient
US12/583,177 2009-08-13
USPCT/US2009/004659 2009-08-13
US30590110P 2010-02-18 2010-02-18
US61/305,901 2010-02-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012109393/10A Division RU2592670C2 (ru) 2009-08-13 2010-08-13 Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017145301A Division RU2732229C3 (ru) 2017-12-22 Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов

Publications (1)

Publication Number Publication Date
RU2642302C1 true RU2642302C1 (ru) 2018-01-24

Family

ID=43586530

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016123808A RU2642302C1 (ru) 2009-08-13 2010-08-13 Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
RU2012109393/10A RU2592670C2 (ru) 2009-08-13 2010-08-13 Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012109393/10A RU2592670C2 (ru) 2009-08-13 2010-08-13 Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов

Country Status (13)

Country Link
EP (3) EP3117829B1 (https=)
JP (4) JP5909446B2 (https=)
KR (5) KR20180085825A (https=)
CN (7) CN105561295B (https=)
AU (1) AU2010282361B2 (https=)
BR (2) BR112012003232B1 (https=)
CA (1) CA2770822C (https=)
ES (2) ES2796121T3 (https=)
IL (6) IL287990B (https=)
MX (2) MX2012001916A (https=)
NZ (3) NZ623113A (https=)
RU (2) RU2642302C1 (https=)
WO (1) WO2011020045A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020122745A1 (en) 2018-12-10 2020-06-18 Arshintseva Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
BR112014009528B1 (pt) * 2011-10-17 2020-12-29 Acceleron Pharma, Inc. usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
AU2013334660B2 (en) * 2012-10-24 2018-08-09 Celgene Corporation Methods for treating anemia
CN104968801B (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
MA39722A (fr) * 2014-03-21 2021-06-02 Acceleron Pharma Inc Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
EP3256148A1 (en) * 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
MA42160A (fr) * 2015-05-20 2018-03-28 Maria Cappellini Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
AU2017222526A1 (en) * 2016-02-22 2018-08-23 Acceleron Pharma Inc. ActRII antagonists for use in increasing immune activity
HRP20210694T1 (hr) 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije
PL3490582T3 (pl) * 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
JP7280182B2 (ja) * 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JP2019529509A (ja) 2016-10-05 2019-10-17 アクセレロン ファーマ インコーポレーテッド 腎臓疾患を治療するための組成物および方法
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
HRP20241477T1 (hr) 2017-06-14 2025-01-03 Celgene Corporation Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CN115317589B (zh) * 2022-09-05 2024-12-13 中国海洋大学 脯氨酰羟化酶抑制剂及其应用
CN119198238A (zh) * 2024-09-18 2024-12-27 广东省安家医健健康管理有限公司 一种地中海贫血检测系统及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009463B1 (ru) * 2002-07-26 2007-12-28 Эпоплус Гмбх Унд Ко. Кг Применение эритропоэтина
WO2008076437A2 (en) * 2006-12-18 2008-06-26 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
WO2008097541A2 (en) * 2007-02-02 2008-08-14 Acceleron Pharma Inc. Variants derived from actriib and uses therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
AU772694B2 (en) 1999-01-21 2004-05-06 Metamorphix International, Inc. Growth differentiation factor inhibitors and uses therefor
PL219131B1 (pl) * 2000-05-15 2015-03-31 Hoffmann La Roche Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CN102552263A (zh) * 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
DK1592416T3 (da) * 2003-02-07 2009-04-20 Prometic Biosciences Inc Fedtsyrer med middel kædelængde, glycerider og analoger som stimulatorer af erythropoiesis
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
BRPI0518728A2 (pt) * 2004-12-09 2008-12-02 Univ Pittsburgh vacinas para a resposta rÁpida À pandemia de gripe aviÁria
JPWO2006115274A1 (ja) * 2005-04-26 2008-12-18 味の素株式会社 骨髄赤血球前駆細胞分化促進剤
WO2007042169A2 (en) * 2005-10-07 2007-04-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Matrix metalloproteinase 11 vaccine
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2008073292A2 (en) * 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
JP5773868B2 (ja) * 2008-06-26 2015-09-02 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用
SMT202300222T1 (it) * 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009463B1 (ru) * 2002-07-26 2007-12-28 Эпоплус Гмбх Унд Ко. Кг Применение эритропоэтина
WO2008076437A2 (en) * 2006-12-18 2008-06-26 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
WO2008097541A2 (en) * 2007-02-02 2008-08-14 Acceleron Pharma Inc. Variants derived from actriib and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HSIEH M.M. et al., HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques, Blood, 2007, v.110, n.6, p.2140-2147. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020122745A1 (en) 2018-12-10 2020-06-18 Arshintseva Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
US12310982B2 (en) 2018-12-10 2025-05-27 Elena Valentinovna ARSHINTSEVA Use of the poloxamer as a pharmacologically active substance

Also Published As

Publication number Publication date
CN105535938B (zh) 2022-04-26
IL287990B (en) 2022-07-01
CN113171442A (zh) 2021-07-27
IL218052A0 (en) 2012-04-30
WO2011020045A1 (en) 2011-02-17
JP2018177816A (ja) 2018-11-15
CN113082194B (zh) 2025-03-18
RU2020127574A (ru) 2022-02-21
CN102655872B (zh) 2016-01-20
CA2770822C (en) 2020-03-24
CN113082194A (zh) 2021-07-09
IL252045A0 (en) 2017-06-29
IL252045B (en) 2020-05-31
CN105561295B (zh) 2020-03-20
HK1223818A1 (zh) 2017-08-11
AU2010282361B2 (en) 2015-03-19
CN113171442B (zh) 2024-11-15
IL252046B (en) 2020-07-30
MX2012001916A (es) 2012-05-22
KR20120054024A (ko) 2012-05-29
NZ623113A (en) 2015-10-30
CN105412908B (zh) 2021-08-24
KR20230003452A (ko) 2023-01-05
ES2796121T3 (es) 2020-11-25
AU2010282361A1 (en) 2012-03-15
IL287990A (en) 2022-01-01
EP2464369A1 (en) 2012-06-20
KR20180085825A (ko) 2018-07-27
NZ598348A (en) 2014-05-30
IL252046A0 (en) 2017-06-29
CN105561295A (zh) 2016-05-11
KR20200124322A (ko) 2020-11-02
IL252044B (en) 2019-11-28
WO2011020045A9 (en) 2011-06-03
CA2770822A1 (en) 2011-02-17
JP2020203953A (ja) 2020-12-24
RU2592670C2 (ru) 2016-07-27
NZ712943A (en) 2017-08-25
IL218052A (en) 2017-05-29
RU2012109393A (ru) 2013-09-20
EP2464369A4 (en) 2013-07-17
MX2019010341A (es) 2019-10-21
CN113577291A (zh) 2021-11-02
KR102170682B1 (ko) 2020-10-28
EP3838919A1 (en) 2021-06-23
RU2017145301A (ru) 2019-06-24
RU2732229C2 (ru) 2020-09-14
ES2844123T3 (es) 2021-07-21
IL252044A0 (en) 2017-06-29
EP2464369B1 (en) 2020-03-11
KR20190111158A (ko) 2019-10-01
JP2016034981A (ja) 2016-03-17
CN105535938A (zh) 2016-05-04
JP2013501816A (ja) 2013-01-17
IL275851A (en) 2020-08-31
JP6860533B2 (ja) 2021-04-14
IL275851B (en) 2021-12-01
JP5909446B2 (ja) 2016-04-26
HK1224199A1 (zh) 2017-08-18
BR112012003232A2 (pt) 2016-11-22
CN105412908A (zh) 2016-03-23
RU2017145301A3 (https=) 2019-06-24
KR102606494B1 (ko) 2023-11-24
KR101882521B1 (ko) 2018-07-27
BR122020019169B1 (pt) 2022-09-27
CN102655872A (zh) 2012-09-05
EP3117829A1 (en) 2017-01-18
BR112012003232B1 (pt) 2022-02-22
EP3117829B1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
JP7329573B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
RU2642302C1 (ru) Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
EP2797620B1 (en) Compositions for treating iron overload in thalassemia
HK40041550A (en) Gdf traps
HK40011608B (en) Compositions for treating myelofibrosis
HK40011608A (en) Compositions for treating myelofibrosis
HK40009493A (en) Gdf traps
HK40009493B (en) Gdf traps
HK1159510A (en) Gdf traps for use to treat anemia
HK1159510B (en) Gdf traps for use to treat anemia
HK1232466B (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1171970A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1171970B (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1232466A1 (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1203413B (en) Compositions for treating iron overload in thalassemia